Literature DB >> 10798813

Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation.

N N Stone1, E R Ratnow, R G Stock.   

Abstract

PURPOSE: Patients with localized prostate cancer who had a prior open prostatectomy or transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH) may be at risk for greater morbidity when treated with brachytherapy. This analysis examines the morbidity following brachytherapy using the real-time method to determine if patients with a history of TURP are at increase risk for developing complications.
MATERIALS AND METHODS: An ultrasound-guided transperineal interactive prostate seed was implanted in 419 patients with T1-T2 prostate cancer. All patients were implanted using a peripheral weighting of sources (75%) with the interior sources placed at least 5 mm from the urethra. The patients were divided into two groups: group 1 consisted of 376 patients (89.7%) without a prior TURP, and group 2 consisted of 43 patients (10.3%) who had a TURP prior to their implant. The mean age, prostate-specific antigen level, Gleason score, clinical stage, prostate volume, isotope implanted, and number of patients treated with neoadjuvant hormone therapy were comparable for both groups.
RESULTS: Median follow-up for group 1 was 12 months and for group 2 was 18 months. No patients suffered from radiation-related proctitis or cystitis in either group of patients. Two patients in group 2 implanted with iodine 125 and who had a history of two prior TURPs developed mild superficial urethral necrosis (SUN). The actuarial freedom from developing superficial urethral necrosis at 4 years was 84% in patients with a history of prior TURP. There were no episodes of SUN in group 1 and no cases of incontinence reported in either group of patients. The actuarial rate of potency was 78% at 2 years.
CONCLUSION: Whereas other techniques of seed implantation report incontinence in patients who had a prior open prostatectomy or TURP, the real-time method combined with peripheral loading avoids this complication.

Entities:  

Mesh:

Year:  2000        PMID: 10798813

Source DB:  PubMed          Journal:  Tech Urol        ISSN: 1079-3259


  9 in total

1.  Advances in brachytherapy.

Authors:  Peter Grimm; John Sylvester
Journal:  Rev Urol       Date:  2004

Review 2.  [Curative radiotherapy of localized prostate cancer. Treatment methods and results].

Authors:  R Schwarz
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

Review 3.  Permanent interstitial brachytherapy for prostate cancer: a current review.

Authors:  Jeffrey Woolsey; Nicole Miller; Dan Theodorescu
Journal:  World J Urol       Date:  2003-08-13       Impact factor: 4.226

4.  Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer?

Authors:  Ahmed ElShafei; Molly DeWitt-Foy; Adam Calaway; Austin J Fernstrum; Adonis Hijaz; Wade Muncey; Anood Alfahmy; Amr Mahran; Kirtishri Mishra; J Stephen Jones; Thomas J Polascik
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-01-22       Impact factor: 5.554

5.  Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer.

Authors:  Seth R Blacksburg; Donald B Fuller; Jonathan A Haas
Journal:  Front Oncol       Date:  2020-12-15       Impact factor: 6.244

Review 6.  Permanent seed implantation for localized adenocarcinoma of the prostate.

Authors:  Nelson N Stone; Richard G Stock
Journal:  Curr Urol Rep       Date:  2002-06       Impact factor: 2.862

7.  Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection.

Authors:  Carl Salembier; Alex Rijnders; Ann Henry; Peter Niehoff; Frank André Siebert; Peter Hoskin
Journal:  J Contemp Brachytherapy       Date:  2013-06-28

8.  Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Longterm results.

Authors:  Pedro J Prada; Javier Anchuelo; Ana Garcia Blanco; Gema Paya; Juan Cardenal; Enrique Acuna; Maria Ferri; Andres Vazquez; Maite Pacheco; Jesica Sanchez
Journal:  Int Braz J Urol       Date:  2016 Jan-Feb       Impact factor: 1.541

9.  A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate 125I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial.

Authors:  Carl Salembier; Ann Henry; Bradley R Pieters; Peter Hoskin
Journal:  J Contemp Brachytherapy       Date:  2020-02-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.